📊 CATX Key Takeaways
Is Perspective Therapeutics, Inc. (CATX) a Good Investment?
Perspective Therapeutics faces critical financial distress with only $1.4M in quarterly revenue against $31.5M in operating cash burn, resulting in approximately 1.7 quarters of cash runway remaining despite a $54M cash position. The company exhibits the severe operating losses typical of early-stage biotech, but the negligible revenue and accelerating burn rate indicate either failed commercialization or an underdeveloped pipeline with no clear path to profitability.
Perspective Therapeutics has very weak current profitability and cash generation, with minimal revenue, a widening operating loss, and heavy free cash outflow as it scales R&D and manufacturing. However, the balance sheet is unusually strong for a clinical-stage biotech, with low debt, high liquidity, substantial short-term investments, and additional February 2026 financing that appears to extend runway into late 2027. Fundamentally, this is a high-burn, milestone-dependent development story rather than a proven operating business.
Perspective Therapeutics, Inc. Key Strengths (CATX)
- Low debt burden (0.00x Debt/Equity) reduces financial leverage risk
- Strong short-term liquidity ratios (8.75x current ratio) provide near-term solvency
- Substantial asset base ($410.8M) suggests meaningful R&D portfolio and pipeline
- Strong liquidity profile with high current and quick ratios and very low leverage
- Large cash plus short-term investment base, further strengthened by post-year-end equity financing
- R&D investment is accelerating, supporting pipeline advancement and manufacturing build-out
CATX Stock Risks: Perspective Therapeutics, Inc. Investment Risks
- Critical cash runway of approximately 1.7 quarters at current operating burn rate
- Minimal revenue ($1.4M) indicates failed or non-existent product commercialization
- Operating cash flow of -$31.5M per period demonstrates unsustainable business model without external funding or major operational improvement
- Equity will be severely diluted through necessary capital raises to extend runway
- Revenue quality is weak because current revenue is largely grant-based rather than product commercialization
- Operating losses and free cash flow burn are severe and increased materially year over year
- Business remains dependent on clinical, regulatory, and future financing success before reaching sustainable profitability
Key Metrics to Watch
- Cash balance depletion rate and cash runway extension
- Quarterly revenue growth and product commercialization progress
- Operating cash burn trend and path to breakeven
- Capital raise announcements and dilution impact on shareholders
- Quarterly operating cash burn relative to cash plus short-term investments runway
- Clinical progress and any transition from grant revenue toward meaningful commercial or partnership revenue
Perspective Therapeutics, Inc. (CATX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.75x current ratio provides a solid financial cushion.
CATX Profit Margin, ROE & Profitability Analysis
CATX vs Healthcare Sector: How Perspective Therapeutics, Inc. Compares
How Perspective Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Perspective Therapeutics, Inc. Stock Overvalued? CATX Valuation Analysis 2026
Based on fundamental analysis, Perspective Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Perspective Therapeutics, Inc. Balance Sheet: CATX Debt, Cash & Liquidity
CATX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Perspective Therapeutics, Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-1.23 indicates the company is currently unprofitable.
CATX Revenue Growth, EPS Growth & YoY Performance
CATX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $1.7M | -$371.0K | $-0.03 |
| Q2 2023 | $1.5M | -$371.0K | $-0.01 |
| Q1 2023 | $1.7M | -$371.0K | $0.00 |
| Q3 2022 | $2.6M | -$713.0K | $-0.01 |
| Q2 2022 | $2.4M | -$713.0K | N/A |
| Q1 2022 | $2.4M | -$713.0K | N/A |
| Q3 2021 | $2.6M | -$545.0K | N/A |
| Q2 2021 | $2.2M | -$713.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Perspective Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CATX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Perspective Therapeutics, Inc. (CIK: 0000728387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CATX
What is the AI rating for CATX?
Perspective Therapeutics, Inc. (CATX) has a Combined AI Grade of C from Claude (D) and ChatGPT (B) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CATX's key strengths?
Claude: Low debt burden (0.00x Debt/Equity) reduces financial leverage risk. Strong short-term liquidity ratios (8.75x current ratio) provide near-term solvency. ChatGPT: Strong liquidity profile with high current and quick ratios and very low leverage. Large cash plus short-term investment base, further strengthened by post-year-end equity financing.
What are the risks of investing in CATX?
Claude: Critical cash runway of approximately 1.7 quarters at current operating burn rate. Minimal revenue ($1.4M) indicates failed or non-existent product commercialization. ChatGPT: Revenue quality is weak because current revenue is largely grant-based rather than product commercialization. Operating losses and free cash flow burn are severe and increased materially year over year.
What is CATX's revenue and growth?
Perspective Therapeutics, Inc. reported revenue of $1.4M.
Does CATX pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
Where can I find CATX SEC filings?
Official SEC filings for Perspective Therapeutics, Inc. (CIK: 0000728387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CATX's EPS?
Perspective Therapeutics, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CATX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Perspective Therapeutics, Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CATX stock overvalued or undervalued?
Valuation metrics for CATX: ROE of -7.5% (sector avg: 15%), net margin of -1,826.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CATX's AI grade for 2026?
Our dual AI analysis gives Perspective Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CATX's free cash flow?
Perspective Therapeutics, Inc.'s operating cash flow is $-31.5M, with capital expenditures of $6.9M. FCF margin is -2,672.7%.
How does CATX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,826.3% (avg: 12%), ROE -7.5% (avg: 15%), current ratio 8.75 (avg: 2).